Cellyrix is transforming cancer treatment by uniquely addressing tumor heterogeneity, the root of resistance and relapse. Our proprietary platform leverages cutting-edge single-cell RNA sequencing and AI-powered computational analysis to discover and develop novel cell state modulators. This groundbreaking approach, unlike traditional therapies, reprogrammed malignant cell states to become benign and drug-responsive, promising significantly improved patient outcomes and a powerful competitive edge in the oncology market.